glutathion tripeptid 5.2 Peptide Structure of the tripeptide glutathione

7 In the phase 2 monotherapy trial these events were generally mild to moderate, most frequent during dose escalation, and tended to diminish with continued treatment

Intrinsic factor replacement therapy is typically recommended for individuals who have Type 1 pernicious anemia and have an autoimmune disorder that affects the stomach's ability to produce intrinsic factor

Adverse Reactions: length of treatment is directly related to the dogs ability to tolerate the medication and to possible side effects of the medication

To be effective, glutathione should be delivered in a liposomal format

Necropsy confirmed splenomegaly and lymph node enlargement (Fig